6296-53-3Relevant academic research and scientific papers
Synthetic method of apremilast
-
Paragraph 0009; 0027-0029; 0034-0036; 00038-0040, (2021/07/17)
The invention relates to a synthesis method of apremilast, which comprises the following steps: (1): reacting 3-aminophthalic acid or salt thereof with acetic anhydride to obtain 3-acetamido phthalic anhydride; and (2) suspending 3-acetamido phthalic anhydride in a first solvent, adding into a suspension consisting of free amine (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl) ethylamine and a second solvent at a certain temperature, reacting, and adding a C1-C6 alcohol solvent for crystallization after the reaction is finished, thereby obtaining the apremilast. According to the synthesis method of apremilast, the production cost is reduced, the operation process is facilitated, the safety in industrial production is improved to a great extent, the yield is high, and the effect is good.
ISOINDOLE DERIVATIVE
-
Paragraph 0227, (2021/02/25)
Disclosed is a compound of formula (I) and a stereoisomer thereof: wherein R1, R2, R3 and R4 are as defined in the present disclosure.
Synthesis method of methyl 2-acetyl-6-aminobenzoate
-
Paragraph 0055; 0059; 0060; 0069; 0073; 0074, (2020/05/01)
The invention provides a synthesis method of methyl 2-acetyl-6-aminobenzoate. The target product methyl 2-acetyl-6-aminobenzoate is prepared from cheap and easily available 3-nitrophthalic acid through a six-step reaction. The synthesis method has the characteristics of easily available raw materials, short route, high yield, easiness in operation, small environmental pollution and the like, and is suitable for large-scale industrial production.
Apremilast three-component one-pot-boiling synthesis method
-
Paragraph 0031-0039; 0044, (2019/11/29)
The invention provides an apremilast three-component one-pot-boiling synthesis method. According to the apremilast three-component one-pot-boiling synthesis method, 3-aminophthalic acid, (S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethylamine N-acetyl-L-leucine salt, and acetic anhydride are taken as raw materials to prepare apremilast through one-pot-boiling method. The apremilast three-component one-pot-boiling synthesis method is simple and convenient in operation, high in yield, low in pollution, and is suitable for large scale preparation.
NOVEL PROCESS TO PREPARE N-[2-[(1S)-1-(3-ETHOXY-4-METHOXYPHENYL)-2-(METHYLSULPHONYL) ETHYL]-1, 3-DIOXO-2,3-DIHYDRO-1H-ISOINDOL-4-YL]ACETAMIDE
-
Page/Page column 12, (2018/12/03)
An alternative and improved process for the preparation of Apremilast (Formula I) and Apremilast form B or a pharmaceutically acceptable salt thereof is provided. The novel process includes hydrogenation in acetone, Cyclization and acetylation followed by condensation in methyl isobutyl ketone (MIBK) and acetic acid mixture in specific volume ratios.
PROCESS FOR PREPARATION OF APREMILAST
-
Paragraph 00114, (2017/03/14)
The present invention relates to a process for preparation of apremilast. The present invention relates to p-xylene solvate of apremilast and process for its preparation.
(+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE: METHODS OF USING AND COMPOSITIONS THEREOF
-
, (2016/01/25)
Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable polymorph, salt, solvate or hydrate thereof, as well as a pharmaceutical composition or single unit dosage form comprising such compound and such compound for use as a medicine.
Preparation method of Apremilast and intermediate
-
, (2016/10/07)
The invention provides a preparation method of Apremilast and its intermediate. The invention provides an Apremilast intermediate as shown in the formula III. According to the preparation method, the compound as shown in the formula III reacts with methanesulfinate to obtain a compound as shown in the formula IV; the compound as shown in the formula IV undergoes reductive amination to obtain a compound as shown in the formula V; the compound as shown in the formula V and asymmetry acid undergo salifying to obtain a compound as shown in the formula VI; and the compound as shown in the formula VI reacts with 3-acetamido-phthalic anhydride to obtain Apremilast. By the method for synthesizing Apremilast, usage of an n-butyllithium hexane solution can be avoided. Production cost is reduced, and operation process is convenient. In addition, safety in the industrial production is raised to a great extent, and the preparation method is more suitable for industrial continuous production. According to the preparation method of 3-acetamido-phthalic anhydride, yield is raised to 81%. As the yield is high, the method provided by the invention is extremely suitable for industrial production of Apremilast.
Preparation method of 3-acetyl aminophthalimide
-
Paragraph 0035; 0036, (2016/10/07)
The invention relates to a preparation method of 3-acetyl aminophthalimide, comprising the following steps: dissolving 3-nitro phthalic acid in sodium hydroxide aqueous solution, then adding a reducer and a catalyst, heating to 70 to 80 DEG C, stirring and reacting for 1 to 20 hours, and recrystallizing to obtain 3-amino phthalic acid; stirring with acetic anhydride and performing reflux reaction for 1 to 10 hours to obtain N-(1,3-Dioxo-1,3-dihydro-2-benzofuran-4-yl)acetamide; dissolving the N-(1,3-Dioxo-1,3-dihydro-2-benzofuran-4-yl)acetamide in an organic solvent, adding an amino donor, and stirring and refluxing for 1 to 10 hours, thus obtaining the 3-acetyl aminophthalimide. The method is simple in operation, high in yield, short in reaction route, less in the three wastes (waste gas industrial residue), and easy for industrial production.
DOSAGE TITRATION OF APREMILAST FOR THE TREATMENT OF DISEASES AMELIORATED BY PDE4 INHIBITION
-
Paragraph 0095, (2016/02/29)
Administration of apremilast in a specific dosage titration schedule, alone or in combination with a second active agent for use in methods of treating, managing or preventing diseases ameliorated by inhibiting PDE4 such as psoriasis, ankylosing spondylitis, Behcet's disease, rheumatoid arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis.

